-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Moroxydine API
Category:
TIME：2025-08-19
On August 19, the morpholine nitrazole active pharmaceutical ingredient developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms. This marks the ninth new API product approved for Guangxiang Pharmaceutical so far this year.
According to available information, moroxydine nitrate is indicated for the treatment of the following infections in adults (≥18 years) caused by susceptible bacteria: pelvic inflammatory disease in gynecology, suppurative appendicitis requiring combined surgical management, and gangrenous appendicitis, among others.
In recent years, the Group has consistently advanced integrated development of “active pharmaceutical ingredients (APIs) plus finished dosage forms.” Its API R&D capabilities have steadily accumulated and now are yielding significant results, with 15 new API products approved this year. To date, the Group boasts a portfolio of 82 bulk and specialty APIs, further strengthening its ability to secure supply chains for both the company and the broader industry.
Keywords:
Previous
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
